NICOLE DEBETTENCOURT: Open Payments
NPI 1235471244 · ANNAPOLIS, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$766 in 30 payments from 12 companies in 2025. Trend: 2023 $257 · 2024 $976 · 2025 $766
Food & beverage: $766
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 7 | $160 |
| Ipsen Biopharmaceuticals, Inc | 5 | $133 |
| Janssen Biotech, Inc. | 2 | $116 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $85 |
| Mallinckrodt Hospital Products Inc. | 2 | $63 |
| ORPHALAN INC | 3 | $62 |
| Gilead Sciences, Inc. | 2 | $33 |
| GENZYME CORPORATION | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Novo Nordisk Inc | 1 | $21 |
Products named: REZDIFFRA, IQIRVO, TREMFYA, XIFAXAN, TERLIVAZ, CUVRIOR, DUPIXENT, EOHILIA.
Industry payments across MD — which companies pay providers there.
